Maze Therapeutics (MAZE) Competitors $15.04 -0.15 (-0.99%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock MAZE vs. CNTA, DNLI, AGIO, IBRX, IDYA, HRMY, RXRX, OCUL, IRON, and BLTEShould you be buying Maze Therapeutics stock or one of its competitors? The main competitors of Maze Therapeutics include Centessa Pharmaceuticals (CNTA), Denali Therapeutics (DNLI), Agios Pharmaceuticals (AGIO), ImmunityBio (IBRX), IDEAYA Biosciences (IDYA), Harmony Biosciences (HRMY), Recursion Pharmaceuticals (RXRX), Ocular Therapeutix (OCUL), Disc Medicine (IRON), and Belite Bio (BLTE). These companies are all part of the "pharmaceutical products" industry. Maze Therapeutics vs. Its Competitors Centessa Pharmaceuticals Denali Therapeutics Agios Pharmaceuticals ImmunityBio IDEAYA Biosciences Harmony Biosciences Recursion Pharmaceuticals Ocular Therapeutix Disc Medicine Belite Bio Centessa Pharmaceuticals (NASDAQ:CNTA) and Maze Therapeutics (NASDAQ:MAZE) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership. Is CNTA or MAZE more profitable? Maze Therapeutics' return on equity of 0.00% beat Centessa Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Centessa PharmaceuticalsN/A -40.39% -29.87% Maze Therapeutics N/A N/A N/A Do institutionals & insiders hold more shares of CNTA or MAZE? 82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 7.1% of Centessa Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has higher valuation & earnings, CNTA or MAZE? Maze Therapeutics has higher revenue and earnings than Centessa Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCentessa Pharmaceuticals$6.85M308.68-$235.76M-$1.79-8.82Maze Therapeutics$167.50M3.94$52.23MN/AN/A Does the media refer more to CNTA or MAZE? In the previous week, Maze Therapeutics had 1 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 17 mentions for Maze Therapeutics and 16 mentions for Centessa Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 1.09 beat Maze Therapeutics' score of 0.97 indicating that Centessa Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Centessa Pharmaceuticals 8 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Maze Therapeutics 7 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer CNTA or MAZE? Centessa Pharmaceuticals currently has a consensus price target of $31.45, indicating a potential upside of 99.21%. Maze Therapeutics has a consensus price target of $26.33, indicating a potential upside of 75.09%. Given Centessa Pharmaceuticals' higher probable upside, equities research analysts clearly believe Centessa Pharmaceuticals is more favorable than Maze Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Centessa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 3.08Maze Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25 SummaryMaze Therapeutics beats Centessa Pharmaceuticals on 7 of the 13 factors compared between the two stocks. Get Maze Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MAZE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MAZE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MAZE vs. The Competition Export to ExcelMetricMaze TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$666.09M$3.13B$5.76B$9.85BDividend YieldN/A2.28%6.71%4.51%P/E RatioN/A7.5859.1122.53Price / Sales3.94458.96547.00119.09Price / Cash99.2244.5237.0558.92Price / Book-2.129.9310.916.06Net Income$52.23M-$53.38M$3.29B$266.28M7 Day Performance5.40%0.05%0.01%-0.76%1 Month Performance-1.38%7.08%7.06%3.83%1 Year PerformanceN/A11.92%50.09%24.39% Maze Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MAZEMaze TherapeuticsN/A$15.04-1.0%$26.33+75.1%N/A$666.09M$167.50M0.00121News CoverageAnalyst ForecastCNTACentessa Pharmaceuticals3.5162 of 5 stars$17.01-3.0%$28.10+65.2%+17.9%$2.28B$15M-9.50200News CoveragePositive NewsAnalyst ForecastDNLIDenali Therapeutics4.351 of 5 stars$15.49+1.7%$33.62+117.0%-39.1%$2.23B$330.53M-5.53430Positive NewsAGIOAgios Pharmaceuticals4.3893 of 5 stars$38.80+1.6%$56.33+45.2%-9.2%$2.22B$36.50M3.53390News CoveragePositive NewsAnalyst ForecastOptions VolumeGap DownIBRXImmunityBio2.5054 of 5 stars$2.31+3.1%$10.75+365.4%-35.9%$2.18B$56.60M-4.81590IDYAIDEAYA Biosciences4.4336 of 5 stars$25.12+2.0%$48.09+91.4%-32.4%$2.16B$7M-6.6380Trending NewsAnalyst ForecastAnalyst RevisionHRMYHarmony Biosciences4.3059 of 5 stars$37.86+1.5%$51.00+34.7%+3.2%$2.15B$772.53M12.21200News CoveragePositive NewsRXRXRecursion Pharmaceuticals2.303 of 5 stars$4.94+3.3%$7.00+41.7%-23.7%$2.14B$64.51M-2.78400OCULOcular Therapeutix3.438 of 5 stars$12.30+1.4%$17.20+39.8%+55.0%$2.11B$63.72M-9.61230IRONDisc Medicine3.3184 of 5 stars$60.35+1.0%$98.30+62.9%+24.1%$2.08BN/A-13.5030Positive NewsBLTEBelite Bio2.2901 of 5 stars$64.40-1.2%$96.67+50.1%+31.2%$2.05BN/A-41.5510 Related Companies and Tools Related Companies Centessa Pharmaceuticals Competitors Denali Therapeutics Competitors Agios Pharmaceuticals Competitors ImmunityBio Competitors IDEAYA Biosciences Competitors Harmony Biosciences Competitors Recursion Pharmaceuticals Competitors Ocular Therapeutix Competitors Disc Medicine Competitors Belite Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MAZE) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s national nightmare is hereWashington just added $1 trillion to the national debt in less than two months — an astonishing pace of spendi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maze Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maze Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
